Commenting about the trial during an interview, session cochair Dr Georg Schett (Medical University of Vienna, Austria) called the trial "an important story." He added that the findings confirm the ...

A 46-year-old man presents for his first dermatology consultation for worsening symptoms of plaque psoriasis and recent-onset joint pain. He reports “painful aching” and swelling of his finger joints, ...

Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — Patients with juvenile idiopathic arthritis started on conventional synthetic and biologic ...

Biologic response modifiers presently approved in the USA for use in various rheumatic inflammatory diseases include three TNF inhibitors (etanercept, infliximab and adalimumab), a B-cell-directed ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Since 2008, there has been no “consistent increase” in ...

No increased risk for cancer was found among patients with RA receiving biologic or targeted synthetic DMARDs vs TNF inhibitors.

A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this 12-part journey ...

New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, showed that combining a nonsteroidal anti-inflammatory drug and TNF inhibitor did not ...